home / stock / cntx / cntx news


CNTX News and Press, Context Therapeutics Inc.

Stock Information

Company Name: Context Therapeutics Inc.
Stock Symbol: CNTX
Market: NASDAQ
Website: contexttherapeutics.com

Menu

CNTX CNTX Quote CNTX Short CNTX News CNTX Articles CNTX Message Board
Get CNTX Alerts

News, Short Squeeze, Breakout and More Instantly...

CNTX - Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology breakthro...

CNTX - Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today shared two po...

CNTX - Context Therapeutics GAAP EPS of -$0.10 misses by $0.01

2025-11-06 09:21:40 ET More on Context Therapeutics Seeking Alpha’s Quant Rating on Context Therapeutics Historical earnings data for Context Therapeutics Financial information for Context Therapeutics Read the full article on Seeking Alpha For...

CNTX - Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9 million as of September 30, 2025 PHILADELPHIA, Nov. 05, 2025...

CNTX - Expected US Company Earnings on Wednesday, November 5th, 2025

Curaleaf Holdings Inc (CURLF) is expected to report $-0.07 for Q3 2025 Southwest Gas Holdings Inc. (DE) (SWX) is expected to report $0.09 for Q3 2025 Terreno Realty Corporation (TRNO) is expected to report $0.65 for Q3 2025 Bio-Techne Corp (TECH) is expected to report $0.36 for Q1 202...

CNTX - Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

Karen Smith, MD, PhD, MBA, LLM, joins with over 25 years of global pharma and biotech experience, having contributed to more than 20 regulatory approvals Dr Smith's appointment will accelerate Step Pharma's ‘pipeline in a product’ strategy, leveraging her clinical and regula...

CNTX - Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced two...

CNTX - Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted ...

CNTX - Context Therapeutics reports Q2 results

2025-08-07 11:33:41 ET More on Context Therapeutics Context Therapeutics: Undervalued Cancer Fighter Seeking Alpha’s Quant Rating on Context Therapeutics Historical earnings data for Context Therapeutics Financial information for Context Therapeutics ...

CNTX - Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeut...

Next 10